[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"trial:NCT07521007":3,"trial-entities:NCT07521007":499,"trial-summary:NCT07521007":503},{"id":4,"nct_id":4,"org_study_id":5,"brief_title":6,"official_title":7,"overall_status":8,"completion_date":9,"status_verified_date":10,"last_update_date":11,"start_date":12,"sponsor_name":13,"lead_sponsor_class":14,"has_dmc":15,"brief_summary":16,"detailed_description":17,"conditions":18,"keywords":21,"study_type":24,"primary_purpose":25,"phases":26,"enrollment_info":28,"interventions":31,"primary_outcomes":48,"secondary_outcomes":53,"sex":100,"minimum_age":101,"maximum_age":102,"healthy_volunteers":103,"eligibility_criteria":104,"std_ages":111,"locations":114,"central_contacts":485,"overall_officials":493,"references":497,"see_also_links":498},"NCT07521007","YN001-203","A Phase 2b Clinical Trial of YN001 in Adults With Coronary Atherosclerosis","A Randomized, Multicenter, Double-Blind, Parallel, Placebo-controlled Phase 2b Clinical Trial to Evaluate the Efficacy and Safety of YN001 in Adults With Coronary Atherosclerosis","RECRUITING","2029-03-31","2026-08","2026-08-04","2026-07-31","Beijing Inno Medicine Co., Ltd.","INDUSTRY",true,"This study is designed to evaluate the efficacy and safety of intravenously administered YN001 in patients diagnosed with coronary atherosclerosis, who are receiving background therapy for cardiovascular (CV) risk factors management.","This is a multinational, multicenter, randomized, parallel, double-blind, placebo-controlled clinical trial to evaluate the efficacy and safety of intravenously administered YN001 compared with placebo in participants with coronary atherosclerosis who are receiving background therapy for CV risk factors management.\n\nA total of 456 participants are expected to be enrolled. The study will consist of a maximum 12-week screening\u002FBaseline period, followed by a 12-week blinded treatment period, a 30-day safety follow-up, and a long-term follow-up period through Week 96 (approximately 2 years after randomization).",[19,20],"Atherosclerosis","Coronary Artery Disease",[22,23],"Plaque regression","Plaque stabilization","INTERVENTIONAL","TREATMENT",[27],"PHASE2",{"count":29,"type":30},456,"ESTIMATED",[32,38,43],{"type":33,"name":34,"description":35,"armGroupLabels":36},"DRUG","YN001\u002FPlacebo 40mg","Dose 1 YN001\u002FPlacebo 40mg will be administrated on Day 1 of each week from Week 1 to Week 13, 13 times in total.",[37],"Dose 1 YN001\u002FPlacebo 40mg",{"type":33,"name":39,"description":40,"armGroupLabels":41},"YN001\u002FPlacebo 20mg","YN001\u002FPlacebo 20mg will be administrated on Day 1 of each week from Week 1 to Week 13, 13 times in total.",[42],"Dose 2 YN001\u002FPlacebo 20mg",{"type":33,"name":44,"description":45,"armGroupLabels":46},"YN001\u002FPlacebo 0mg","YN001\u002FPlacebo 0mg will be administrated on Day 1 of each week from Week 1 to Week 13, 13 times in total.",[47],"Dose 3 YN001\u002FPlacebo 0mg",[49],{"measure":50,"description":51,"timeFrame":52},"Relative change from baseline in coronary NCPV at Week 13","Relative change in coronary NCPV from baseline to Week 13 as determined by coronary computed tomography angiography (CCTA)","Baseline to Week 13",[54,58,61,64,68,71,75,79,83,87,90,93,97],{"measure":55,"description":56,"timeFrame":57},"Absolute change from baseline in carotid intima-media thickness (IMT) at Week 13","Absolute change in carotid IMT from baseline to Week 13 as determined by carotid ultrasound.","From baseline to Week 13",{"measure":59,"description":59,"timeFrame":60},"Absolute change from baseline in carotid intima-media thickness (IMT) at Week 9","From baseline to Week 9",{"measure":62,"description":63,"timeFrame":57},"Relative change from baseline in carotid intima-media thickness (IMT) at Week 13","Relative change in carotid IMT from baseline to Week 13 as determined by carotid ultrasound",{"measure":65,"description":66,"timeFrame":67},"Relative change in the maximum thickness and area of carotid plaque at Week 9, and Week 13","Relative change in the maximum thickness and area of carotid plaque from baseline to Week 9, and Week 13 as determined by carotid ultrasound","From baseline to Week 9 and Week 13",{"measure":69,"description":70,"timeFrame":57},"Relative change in coronary Percent Atheroma Volume (PAV) at Week 13","Relative change in coronary Percent Atheroma Volume (PAV) from baseline to Week 13 as determined by CCTA",{"measure":72,"description":73,"timeFrame":74},"Relative change in coronary Low Attenuation Plaque Volume(LAPV) at Week 13","Relative change in coronary LAPV from baseline to Week 13 as determined by CCTA.","From baseline to week 13",{"measure":76,"description":77,"timeFrame":78},"Relative changes in coronary NCPV, PAV, TAV, and LAPV from baseline at 48 week","Relative changes in coronary NCPV, PAV, TAV, and LAPV from baseline to Week 48 as determined by CCTA","From baseline to week 48",{"measure":80,"description":81,"timeFrame":82},"Absolute change in coronary NCPV at week 13 and week 48","Absolute change in coronary NCPV from baseline to Week 13 and Week 48 as determined by CCTA","From baseline to week 13 and week 48",{"measure":84,"description":85,"timeFrame":86},"Time to First Occurrence of Any Component of the Major Adverse Cardiac Event (MACE)","Time to the first occurrence of the MACE, composite of CV death, myocardial infarction (MI), ischemic stroke, urgent coronary revascularization, or hospitalization for unstable angina","From randomization to Week 96",{"measure":88,"description":89,"timeFrame":57},"The safety profile of YN001","Incidence of treatment emergent adverse event (TEAE)\u002Fserious adverse event (SAE)\u002Fadverse event of special interest (AESI)",{"measure":91,"description":92,"timeFrame":57},"Immunogenicity (ADA) analysis","Incidence of anti-drug antibodies (ADA) formation",{"measure":94,"description":95,"timeFrame":96},"Immunogenicity (APA) analysis","Incidence of anti-PEG antibodies (APA) formation","From baseline to Week 17",{"measure":98,"description":99,"timeFrame":57},"YN001 concentrations analysis in plasma","Sparse blood samples will be collected, and these concentrations are intended to be pooled with other studies to develop\u002Fupdate pharmacometric models","ALL","18 Years","80 Years",false,{"inclusion":105,"exclusion":109,"raw_text":110},[106,107,108],"Current cigarette smoker","Hypertension","Estimated glomerular filtration rate (eGFR) 45 to 60 ml\u002Fmin\u002F1.73m2",[],"Inclusion Criteria:\n\n1. Fully understands the purposes, features, and methods of the study and the possible adverse reactions, and is voluntarily willing to participate in the study, and signs the informed consent form (ICF) before performing any study-specific assessment.\n2. Male or female participants between 18 and 80 years (inclusive, at the time of signing the ICF).\n3. Participants must satisfy either of the following criteria:\n\n1\\) Have clinically evident atherosclerotic CV disease (ASCVD) 2) Meet at least two of the following criteria at screening\u002Fbaseline, as evidenced by:\n\n1. A history of Type 2 diabetes requiring treatment with medication,\n2. Aged \\> 55 years (women) or \\> 50 years (men),\n3. 2 or more of the following atherosclerosis risk factors:\n\n   * Current cigarette smoker\n   * Hypertension\n   * Estimated glomerular filtration rate (eGFR) 45 to 60 ml\u002Fmin\u002F1.73m2\n\n     4\\. Known coronary atherosclerosis as evidenced through coronary angiography or CCTA. The following criteria must be met on the core lab CCTA interpretation for the patient to be enrolled: at least one epicardial coronary artery with a lumen stenosis of 25% to 69%, total coronary NCPV is at least 75 mm3, Detectable low-attenuation composition in one or more individual plaques.\n\n     5\\. Female participants must be non-pregnant and non-lactating\n\n     6\\. Willing and able to comply with the requirements of protocol to the best of the participant's and investigator's knowledge.\n\nExclusion Criteria:\n\n1. Prior treatment with other investigational drug(s) within 30 days or 5 half-lives, whichever is longer, prior to randomization.\n2. Previously received YN001.\n3. Any type of vaccination within 4 weeks prior to randomization, or any planned vaccination during the study treatment period\n4. Contraindication for CCTA\n5. 3 major epicardial coronary arteries with ≥ 70% or left main ≥50% stenosis.\n6. Acute MI that occurred within 4 weeks prior to randomization.\n7. PCI performed within 2 weeks prior to randomization or PCI is required or planned during study treatment based on clinical indication for revascularization.\n8. Clinically evident stroke or transient ischemic attack (TIA) within 6 months prior to randomization.\n9. Relapse and highly symptomatic arrhythmia uncontrolled by drugs within the past 3 months.\n10. Prior coronary artery bypass graft (CABG), aortic root surgery with coronary reimplantation, left ventricular assist device (LVAD) placement, surgical aortic valve replacement (SAVR), transcatheter aortic valve replacement (TAVR), or heart transplantation, or a plan to undergo these procedures (CABG, aortic root surgery with coronary reimplantation, LVAD placement, SAVR, TAVR, or heart transplantation) during the study.\n11. New York Heart Association class III or IV or last known left ventricular ejection fraction (LVEF) was \\\u003C40%.\n12. Carotid endarterectomy or stenting, peripheral arterial revascularization, or abdominal aortic aneurysm repair within 4 weeks prior to randomization.\n13. History of myopathy or myositis, or susceptibility to myopathy\u002Frhabdomyolysis (e.g., family history of hereditary myopathy, etc.).\n14. History of severe myalgia attributed to statin therapy or other significant concern about statin side effects.\n15. Known gastrointestinal ulcers, inflammatory bowel disease, or gastrointestinal\u002Frectal bleeding within 6 months prior to randomization.\n16. Evidence of unresolved major diseases 2 weeks prior to randomization or planned major surgery during the study that, in the investigator's judgement, may interfere with the investigational product administration or trial assessments.\n17. Presenting with history of malignancy (except in participants who have been disease-free \\>5 years; or whose only malignancy has been basal or squamous cell skin carcinoma).\n18. Presence of any type of autoimmune disease.\n19. Allergy to multiple foods or drugs or known sensitivity to any components to be administered during dosing.\n20. Life expectancy is less than 1 year.\n21. Systolic blood pressure of ≥ 160 mmHg at final screening despite antihypertensive therapy.\n22. Triglycerides ≥ 400 mg\u002FdL (4.5 mmol\u002FL) at final screening.\n23. LDL-C \\> 100 mg\u002FdL (2.6 mmol\u002FL) at final screening.\n24. Active liver disease or hepatic dysfunction defined by any of alanine aminotransaminase (ALT), aspartate aminotransferase (AST), \\> 3 times upper limit of normal (ULN), or total bilirubin \\> 2 times ULN at final screening.\n25. Presence of renal dysfunction, defined by eGFR \\\u003C 45 ml\u002Fmin\u002F1.73m2.\n26. Untreated or inadequately treated hypothyroidism.\n27. Poorly controlled Type 2 diabetes mellitus.\n28. A positive hepatitis B surface antigen (HBsAg), or positive antibody against hepatitis C virus (anti-HCV) or human immunodeficiency virus (anti-HIV), or positive treponema pallidum antibody (TP-Ab).\n29. Presence of any other diseases or conditions (apart from those outlined above) that, in the opinion of the investigator, would make it unsuitable for the participant to participate in this study.",[112,113],"ADULT","OLDER_ADULT",[115,131,144,156,168,181,190,203,215,228,241,254,267,281,291,302,321,335,347,363,379,393,407,421,435,447,461,475],{"facility":116,"status":117,"city":118,"state":119,"zip":120,"country":121,"contacts":122,"geoPoint":128},"Heart Center Research, LLC","NOT_YET_RECRUITING","Huntsville","Alabama","35801","United States",[123],{"name":124,"role":125,"phone":126,"email":127},"Herbert Haught, MD","CONTACT","256-519-8472","hhaught@theheartcenter.md",{"lat":129,"lon":130},34.7304,-86.58594,{"facility":132,"status":117,"city":133,"state":134,"zip":135,"country":121,"contacts":136,"geoPoint":141},"Clinical Trials Research","Lincoln","California","95648",[137],{"name":138,"role":125,"phone":139,"email":140},"Jeffrey Wayne, MD","913-626-9440","jwaynemd@ctrsites.com",{"lat":142,"lon":143},38.89156,-121.29301,{"facility":145,"status":117,"city":146,"state":134,"zip":147,"country":121,"contacts":148,"geoPoint":153},"Stanford University School of Medicine","Stanford","94305",[149],{"name":150,"role":125,"phone":151,"email":152},"Fahim Abbasi, MD","655-724-0954","fahim@stanford.edu",{"lat":154,"lon":155},37.42411,-122.16608,{"facility":157,"status":117,"city":158,"state":134,"zip":159,"country":121,"contacts":160,"geoPoint":165},"Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center","Torrance","90502",[161],{"name":162,"role":125,"phone":163,"email":164},"Budoff Matthew, MD","310-222-4107","mbudoff@lundquist.org",{"lat":166,"lon":167},33.83585,-118.34063,{"facility":169,"status":117,"city":170,"state":171,"zip":172,"country":121,"contacts":173,"geoPoint":178},"Excel Medical Clinical Trials dba Flourish Research - Boca Raton","Boca Raton","Florida","33434",[174],{"name":175,"role":125,"phone":176,"email":177},"Richard Goldman","561-756-8206","rgoldman@flourishresearch.com",{"lat":179,"lon":180},26.35869,-80.0831,{"facility":182,"status":117,"city":183,"state":171,"zip":184,"country":121,"contacts":185},"HCA Florida Heart Institute","Petersburg","33709",[186],{"name":187,"role":125,"phone":188,"email":189},"Robert Sanchez, MD","727-490-2100","robert.sanchez7@hcahealthcare.com",{"facility":191,"status":117,"city":192,"state":193,"zip":194,"country":121,"contacts":195,"geoPoint":200},"Southern Illinois University School of Medicine","Springfield","Illinois","62781",[196],{"name":197,"role":125,"phone":198,"email":199},"Abdul Moiz Hafiz, MD","217-545-8000","ahafiz96@siumed.edu",{"lat":201,"lon":202},39.80172,-89.64371,{"facility":204,"status":117,"city":205,"state":206,"zip":207,"country":121,"contacts":208,"geoPoint":212},"Midwest Heart & Vascular Specialists","Overland Park","Kansas","66209",[209],{"name":210,"role":125,"phone":139,"email":211},"Stepehen Bloom, MD","stephen.bloom@hcahealthcare.com",{"lat":213,"lon":214},38.98223,-94.67079,{"facility":216,"status":117,"city":217,"state":218,"zip":219,"country":121,"contacts":220,"geoPoint":225},"Washington University School of Medicine","St Louis","Missouri","63110",[221],{"name":222,"role":125,"phone":223,"email":224},"Farhan Katchi, MD","314-454-7451","katchif@wustl.edu",{"lat":226,"lon":227},38.62727,-90.19789,{"facility":229,"status":117,"city":230,"state":231,"zip":232,"country":121,"contacts":233,"geoPoint":238},"Wake Forest University Health Sciences","Winston-Salem","North Carolina","27157",[234],{"name":235,"role":125,"phone":236,"email":237},"Michael Shapiro, MD","336-716-2718","michael.shapiro@wfusm.edu",{"lat":239,"lon":240},36.09986,-80.24422,{"facility":242,"status":117,"city":243,"state":244,"zip":245,"country":121,"contacts":246,"geoPoint":251},"The Carl & Edyth Lindner Center for Research & Education at The Christ Hospital","Cincinnati","Ohio","45219",[247],{"name":248,"role":125,"phone":249,"email":250},"Timothy Henry, MD","513-585-1777","timothy.henry@thechristhospital.com",{"lat":252,"lon":253},39.12711,-84.51439,{"facility":255,"status":117,"city":256,"state":257,"zip":258,"country":121,"contacts":259,"geoPoint":264},"Capital Area Research","Camp Hill","Pennsylvania","17011",[260],{"name":261,"role":125,"phone":262,"email":263},"Venkatesh Nadar, MD","717-329-1592","Vnadar@care-research.com",{"lat":265,"lon":266},40.23981,-76.91997,{"facility":268,"status":117,"city":269,"state":270,"zip":271,"country":272,"contacts":273,"geoPoint":278},"Cannopy Clinical Research","Penrith","New South Wales","2750","Australia",[274],{"name":275,"role":125,"phone":276,"email":277},"Karen Kaluhin, MD","0061 0491 276 512","kkaluhin@canopycr.com.au",{"lat":279,"lon":280},-33.75,150.7,{"facility":282,"status":117,"city":283,"state":284,"zip":285,"country":272,"contacts":286},"Canopy Clinical Research","Altona N.","Victoria","3025",[287],{"name":288,"role":125,"phone":289,"email":290},"Oscar Walsh, MD","0061 03 9968 7601","owalsh@canopycr.com.au",{"facility":292,"status":117,"city":293,"state":294,"zip":295,"country":296,"contacts":297},"North York Diagnostic and Cardiac Center","North York","Ontario","M6B 3H7","Canada",[298],{"name":299,"role":125,"phone":300,"email":301},"Subodh Verma, MD","416-864-5997","subodh.verma@unityhealth.to",{"facility":303,"status":117,"city":304,"state":305,"zip":306,"country":307,"contacts":308,"geoPoint":318},"Anhui Provincial Hospital","Hefei","Anhui","230001","China",[309,313,315],{"name":310,"role":125,"phone":311,"email":312},"Kangyu Chen, MD","0086 18056005099","ustccky@126.com",{"name":310,"role":314},"PRINCIPAL_INVESTIGATOR",{"name":316,"role":317},"Chao Gao, MD","SUB_INVESTIGATOR",{"lat":319,"lon":320},31.86389,117.28083,{"facility":322,"status":8,"city":323,"state":324,"zip":325,"country":307,"contacts":326,"geoPoint":332},"Anzhen Hospital","Beijing","Beijing Municipality","100029",[327,331],{"name":328,"role":125,"phone":329,"email":330},"Yuyang Liu, MD","0086 010-64456488","liuyy803803@163.com",{"name":328,"role":314},{"lat":333,"lon":334},39.9075,116.39723,{"facility":336,"status":117,"city":323,"state":324,"zip":337,"country":307,"contacts":338,"geoPoint":346},"Beijing Jishuitan Hospital","100035",[339,343,344],{"name":340,"role":125,"phone":341,"email":342},"Qingwei Ji, MD","0086 18376642655","jqwl24@163.cou",{"name":340,"role":314},{"name":345,"role":314},"Wei Liu, MD",{"lat":333,"lon":334},{"facility":348,"status":117,"city":349,"state":350,"zip":351,"country":307,"contacts":352,"geoPoint":360},"Fujian Medical University Union Hospital","Fuzhou","Fujian","350001",[353,357,358],{"name":354,"role":125,"phone":355,"email":356},"Mingfang Ye, MD","0086 13960818759","xieheyemingfang@163.com",{"name":354,"role":314},{"name":359,"role":317},"Zhaoyang Chen, MD",{"lat":361,"lon":362},26.06139,119.30611,{"facility":364,"status":117,"city":365,"state":366,"zip":367,"country":307,"contacts":368,"geoPoint":376},"The First Affiliated Hospital of Harbin Medical University","Harbin","Heilongjiang","150001",[369,373,374],{"name":370,"role":125,"phone":371,"email":372},"Lu Fu, MD","0086 137 9668 4968","fuluyidayi@163.com",{"name":370,"role":314},{"name":375,"role":314},"Yongtai Gong, MD",{"lat":377,"lon":378},45.75,126.65,{"facility":380,"status":8,"city":381,"state":382,"zip":383,"country":307,"contacts":384,"geoPoint":390},"Zhongnan Hospital of Wuhan University","Wuhan","Hubei","430071",[385,389],{"name":386,"role":125,"phone":387,"email":388},"Zhibing Lu, MD","0086 15997405817","luzhibing222@163.com",{"name":386,"role":314},{"lat":391,"lon":392},30.58333,114.26667,{"facility":394,"status":8,"city":395,"state":396,"zip":397,"country":307,"contacts":398,"geoPoint":404},"The First Hospital of Jilin University","Changchun","Jilin","130033",[399,403],{"name":400,"role":125,"phone":401,"email":402},"Qian Tong, MD","0086 13074337289","tongqian187@aliyun.com",{"name":400,"role":314},{"lat":405,"lon":406},43.88,125.32278,{"facility":408,"status":8,"city":409,"state":410,"zip":411,"country":307,"contacts":412,"geoPoint":418},"The People's Hospital of Liaoning Province","Shenyang","Liaoning","110015",[413,417],{"name":414,"role":125,"phone":415,"email":416},"Ying Liu, MD","0086 13840065379","liuyingwangli@126.com",{"name":414,"role":314},{"lat":419,"lon":420},41.79222,123.43278,{"facility":422,"status":8,"city":423,"state":424,"zip":425,"country":307,"contacts":426,"geoPoint":432},"Renji Hospital Shanghai Jiaotong University school of medicine","Shanghai","Shanghai Municipality","200001",[427,431],{"name":428,"role":125,"phone":429,"email":430},"Jun Bu, MD","0086 13601958108","pujun310@hotmail.com",{"name":428,"role":314},{"lat":433,"lon":434},31.22222,121.45806,{"facility":436,"status":8,"city":423,"state":424,"zip":437,"country":307,"contacts":438,"geoPoint":446},"Fudan University-Zhongshan Hospital","200032",[439,443,444],{"name":440,"role":125,"phone":441,"email":442},"Junbo Ge, MD","021-64041990","ge.junbo@zs-hospital.sh.cn",{"name":440,"role":314},{"name":445,"role":317},"Yuxiang Dai, MD",{"lat":433,"lon":434},{"facility":448,"status":8,"city":449,"state":450,"zip":451,"country":307,"contacts":452,"geoPoint":458},"West China Hospital of Sichuan University","Chengdu","Sichuan","610041",[453,457],{"name":454,"role":125,"phone":455,"email":456},"Yong He, MD","0086 18980602038","zznnyeah@163.com",{"name":454,"role":314},{"lat":459,"lon":460},30.66667,104.06667,{"facility":462,"status":117,"city":463,"state":464,"zip":465,"country":307,"contacts":466,"geoPoint":472},"Tianjin People's Hospital","Tianjin","Tianjin Municipality","300121",[467,471],{"name":468,"role":125,"phone":469,"email":470},"Zhuhua Yao, MD","0086 13902199877","tjyzhpci@163.com",{"name":468,"role":314},{"lat":473,"lon":474},39.14222,117.17667,{"facility":476,"status":117,"city":463,"state":464,"zip":477,"country":307,"contacts":478,"geoPoint":484},"The Second Hospital of Tianjin Medical University","300211",[479,483],{"name":480,"role":125,"phone":481,"email":482},"Tong Liu, MD","0086 13902183163","liutongdoc@126.com",{"name":480,"role":314},{"lat":473,"lon":474},[486,490],{"name":487,"role":125,"phone":488,"email":489},"Jingmei Zhang, Master","0086 010 82599080","zhangjingmei@innovmedicine.com",{"name":491,"role":125,"phone":488,"email":492},"Kaiqi Zong, Master","zongkaiqi@innovmedicine.com",[494],{"name":495,"affiliation":13,"role":496},"Ying Chen, PhD","STUDY_DIRECTOR",[],[],{"nct_id":4,"conditions":500,"biomarkers":502},[501],"Coronary Atherosclerosis",[],{"nct_id":4,"found":15,"summary":504,"prompt_version":514},{"design":505,"status":506,"heading":507,"summary":508,"follow_up":509,"word_count":510,"commitments":511,"compensation":512,"drugs_mentioned":513},"This is a randomized, double-blind, placebo-controlled study involving 456 participants. It compares YN001 to a placebo.","completed","Phase 2b Trial of YN001 for Coronary Atherosclerosis","This study is testing a drug called YN001 in adults with coronary atherosclerosis (a condition where plaque builds up in the arteries of the heart). The goal is to see how well YN001 works and if it's safe when given intravenously (through a vein). You would be between 18 and 80 years old and already receiving treatment for heart disease risk factors. Researchers will compare YN001 at two different doses (20mg and 40mg) to a placebo (an inactive substance). The main way they'll measure success is by looking at changes in coronary NCPV (a measure of plaque) after 13 weeks. The current status of this study is unclear, but it plans to enroll 456 participants.","After the 13-week treatment, there will be a 30-day safety follow-up and a long-term follow-up for about 2 years.",115,"You would receive weekly intravenous doses of YN001 or placebo for 13 weeks. The study involves a screening period, treatment period, and safety follow-up.","Not stated in the trial record.",[],"v2"]